mirtazapine has been researched along with Suicidal Ideation in 12 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Suicidal Ideation: A risk factor for suicide attempts and completions, it is the most common of all suicidal behavior, but only a minority of ideators engage in overt self-harm.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This report used acute treatment data from a clinically representative sample of outpatients with nonpsychotic major depressive disorder (N = 665) participating in the Combining Medications to Enhance Depression Outcomes trial, who received up to 12 weeks of escitalopram, escitalopram plus bupropion SR, or venlafaxine XR plus mirtazapine." | 5.30 | The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation. ( Carmody, TJ; De La Garza, N; Grannemann, BD; Killian, MO; Rush, AJ; Trivedi, MH, 2019) |
| "Prior studies have suggested that major depressive disorder (MDD) with pre-adult onset represents a distinct subtype with greater symptom severity and higher rates of suicidal ideation." | 2.78 | Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report. ( Balasubramani, GK; Kurian, B; Rush, AJ; Sung, SC; Trivedi, MH; Warden, D; Wisniewski, SR; Zisook, S, 2013) |
| "Baseline suicidal ideation was associated with greater depressive severity, childhood neglect, childhood abuse, early major depressive disorder onset, greater psychiatric comorbidity, and worse functioning and quality of life." | 2.76 | Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study. ( Fava, M; Kallenberg, G; Lebowitz, B; Lesser, IM; Luther, JF; Morris, DW; Nierenberg, AA; Rush, AJ; Trivedi, MH; Wisniewski, SR; Zisook, S, 2011) |
| "Major depressive disorders have a significant impact on children and adolescents, including on educational and vocational outcomes, interpersonal relationships, and physical and mental health and well-being." | 2.72 | New generation antidepressants for depression in children and adolescents: a network meta-analysis. ( Badcock, PB; Bailey, AP; Cox, GR; Hetrick, SE; McKenzie, JE; Meader, N; Merry, SN; Moller, CI; Sharma, V, 2021) |
| "Sertraline was the antidepressant most likely to reduce suicidality in our sample." | 1.36 | Was Cipriani right? Audits to compare discharge rates and suicidality between antidepressant monotherapies used in a British community mental health team. ( Agius, M; Gardner, J; Liu, K; Zaman, R, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, S | 1 |
| Lin, M | 1 |
| Rice, T | 1 |
| Coffey, BJ | 1 |
| Lim, SY | 1 |
| Bodagh, N | 1 |
| Scott, G | 1 |
| Hill, NE | 1 |
| Yang, L | 1 |
| Wu, Z | 1 |
| Cao, L | 1 |
| Wang, Y | 2 |
| Su, Y | 1 |
| Huang, J | 1 |
| Fang, M | 1 |
| Yao, Z | 1 |
| Wang, Z | 1 |
| Wang, F | 1 |
| Zhu, Y | 1 |
| Chen, J | 1 |
| Peng, D | 1 |
| Fang, Y | 1 |
| Hetrick, SE | 1 |
| McKenzie, JE | 1 |
| Bailey, AP | 1 |
| Sharma, V | 1 |
| Moller, CI | 1 |
| Badcock, PB | 1 |
| Cox, GR | 1 |
| Merry, SN | 1 |
| Meader, N | 1 |
| Gandotra, K | 1 |
| Chen, P | 1 |
| Jaskiw, GE | 1 |
| Konicki, PE | 1 |
| Strohl, KP | 1 |
| De La Garza, N | 1 |
| Rush, AJ | 3 |
| Killian, MO | 1 |
| Grannemann, BD | 1 |
| Carmody, TJ | 1 |
| Trivedi, MH | 3 |
| Agius, M | 3 |
| Gardner, J | 1 |
| Liu, K | 1 |
| Zaman, R | 3 |
| Holt, C | 2 |
| Butler, S | 2 |
| Zisook, S | 2 |
| Lesser, IM | 1 |
| Lebowitz, B | 1 |
| Kallenberg, G | 1 |
| Wisniewski, SR | 2 |
| Nierenberg, AA | 1 |
| Fava, M | 1 |
| Luther, JF | 1 |
| Morris, DW | 1 |
| Estabrook, KR | 1 |
| Pheister, M | 1 |
| Sung, SC | 1 |
| Balasubramani, GK | 1 |
| Kurian, B | 1 |
| Warden, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol[NCT05814640] | Phase 1/Phase 2 | 520 participants (Anticipated) | Interventional | 2023-02-20 | Recruiting | ||
| Combining Medications to Enhance Depression Outcomes[NCT00590863] | Phase 4 | 665 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Quality of Life Inventory (QOLI) is a 32-item comprehensive self-report of satisfaction in 16 areas of life, such as love, work, and health. Each area is rated in terms of satisfaction and the relationship of that area to overall quality of life. It yields an overall raw score and satisfaction ratings for the 16 individual areas of life. The QOLI raw score is an average of weighted satisfaction ratings computed only over areas of life judged to be Important or Extremely Important to the respondent. Higher scores indicate higher reported quality of life. (NCT00590863)
Timeframe: Measured at Month 7
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram + Bupropion SR | 0.6 |
| Venlafaxine XR + Mirtazapine | 0.4 |
| Escitalopram + Placebo | 0.4 |
Percentage of patients that achieve remission, as defined as QIDS total score below 6 for last 2 study visits. QIDS depression scores range from 0 (normal) to 27 (very severe). (NCT00590863)
Timeframe: Measured at Month 7
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram + Bupropion SR | 46.6 |
| Venlafaxine XR + Mirtazapine | 41.8 |
| Escitalopram + Placebo | 46.0 |
1 review available for mirtazapine and Suicidal Ideation
| Article | Year |
|---|---|
New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Topics: Adolescent; Antidepressive Agents; Bias; Child; Citalopram; Depressive Disorder, Major; Desvenlafaxi | 2021 |
4 trials available for mirtazapine and Suicidal Ideation
| Article | Year |
|---|---|
Predictors and moderators of quality of life in patients with major depressive disorder: An AGTs-MDD study report.
Topics: Citalopram; Depressive Disorder, Major; Female; Humans; Male; Mirtazapine; Quality of Life; Suicidal | 2021 |
The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation.
Topics: Adult; Aged; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Drug Therapy, Combinatio | 2019 |
Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bupropion; Citalopram; Cyclohexanols; Delayed-Action | 2011 |
Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report.
Topics: Adolescent; Adult; Age of Onset; Aged; Antidepressive Agents, Second-Generation; Bupropion; Child Ab | 2013 |
7 other studies available for mirtazapine and Suicidal Ideation
| Article | Year |
|---|---|
Case Report: When Time is of the Essence-Benefits of Mirtazapine in an Adolescent with Major Depressive Disorder and Insomnia, Suicidal Thoughts, and Catatonic Features.
Topics: Adolescent; Depression; Depressive Disorder, Major; Humans; Mirtazapine; Sleep Initiation and Mainte | 2022 |
Hyponatraemia: the importance of obtaining a detailed history and corroborating point-of-care analysis with laboratory testing.
Topics: Aged; Confusion; Humans; Hyponatremia; Inappropriate ADH Syndrome; Male; Medical History Taking; Mir | 2019 |
Effective Treatment of Insomnia With Mirtazapine Attenuates Concomitant Suicidal Ideation.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder; Humans; Male; Middle Aged; Mirtazapine; Sle | 2018 |
Was Cipriani right? Audits to compare discharge rates and suicidality between antidepressant monotherapies used in a British community mental health team.
Topics: Antidepressive Agents; Citalopram; Community Mental Health Services; Cyclohexanols; Depressive Disor | 2010 |
An audit to compare patient factors (age, sex, social background & associated physical diagnoses) in people with refractory depression in a Bedfordshire Community Mental Health Team (BCMHT) being augmented with (A) mirtazepine, (B) atypical antipsychotics
Topics: Adult; Age Distribution; Alcoholism; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Combine | 2011 |
An audit to compare the efficacy of treatment (as indicated by discharge rates and reduction in suicidality) among patients with refractory depression in a Bedfordshire Community Mental Health Team receiving augmentation therapy with either mirtazepine or
Topics: Adult; Age Distribution; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Combined Modality T | 2011 |
A case of quetiapine XR and divalproex-associated neutropenia followed by successful use of ziprasidone.
Topics: Adult; Anti-Anxiety Agents; Antimanic Agents; Antipsychotic Agents; Anxiety Disorders; Bipolar Disor | 2012 |